Neurocrine Biosciences Financial Statements (NBIX)
|
|
|
|
Report date
|
|
|
11.02.2022 |
09.02.2023 |
09.02.2024 |
10.02.2025 |
11.02.2026 |
|
05.05.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
1 134 |
1 489 |
1 887 |
2 355 |
2 861 |
|
3 102 |
|
Operating Income, bln rub |
|
|
102.5 |
249.0 |
250.9 |
570.5 |
619.1 |
|
781.5 |
|
EBITDA, bln rub |
? |
|
138.1 |
264.6 |
416.1 |
639.7 |
666.6 |
|
881.2 |
|
Net profit, bln rub |
? |
|
89.6 |
154.5 |
249.7 |
341.3 |
478.6 |
|
668.6 |
|
|
OCF, bln rub |
? |
|
256.5 |
339.4 |
389.9 |
595.4 |
782.7 |
|
863.7 |
|
CAPEX, bln rub |
? |
|
23.4 |
16.5 |
28.3 |
38.2 |
34.0 |
|
37.2 |
|
FCF, bln rub |
? |
|
233.1 |
322.9 |
361.6 |
557.2 |
748.7 |
|
831.3 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
1 017 |
1 217 |
1 597 |
1 751 |
2 189 |
|
2 264 |
|
Cost of production, bln rub |
|
|
14.3 |
23.2 |
39.7 |
34.0 |
52.1 |
|
56.7 |
|
R&D, bln rub |
|
|
328.1 |
463.8 |
565.0 |
731.1 |
1 016 |
|
1 049 |
|
Interest expenses, bln rub |
|
|
25.8 |
7.10 |
4.60 |
126.6 |
0.000 |
|
0.000 |
|
|
Assets, bln rub |
|
|
2 073 |
2 369 |
3 251 |
3 719 |
4 632 |
|
4 906 |
|
Net Assets, bln rub |
? |
|
1 374 |
1 708 |
2 232 |
2 590 |
3 253 |
|
3 407 |
|
Debt, bln rub |
|
|
440.4 |
262.9 |
428.4 |
455.1 |
415.3 |
|
406.2 |
|
Cash, bln rub |
|
|
711.3 |
989.3 |
1 032 |
1 076 |
1 480 |
|
1 316 |
|
Net debt, bln rub |
|
|
-270.9 |
-726.4 |
-603.2 |
-621.0 |
-1 065 |
|
-910.0 |
|
|
Ordinary share price, rub |
|
|
85.2 |
119.4 |
131.8 |
136.5 |
141.8 |
|
149.6 |
|
Number of ordinary shares, mln |
|
|
94.6 |
95.8 |
97.7 |
100.4 |
99.5 |
|
100.5 |
|
|
Market cap, bln rub |
|
|
8 057 |
11 442 |
12 873 |
13 705 |
14 112 |
|
15 034 |
|
EV, bln rub |
? |
|
7 786 |
10 716 |
12 270 |
13 084 |
13 047 |
|
14 124 |
|
Book value, bln rub |
|
|
1 374 |
1 671 |
2 197 |
2 548 |
3 253 |
|
3 407 |
|
|
EPS, rub |
? |
|
0.95 |
1.61 |
2.56 |
3.40 |
4.81 |
|
6.65 |
|
FCF/share, rub |
|
|
2.46 |
3.37 |
3.70 |
5.55 |
7.52 |
|
8.27 |
|
BV/share, rub |
|
|
14.5 |
17.4 |
22.5 |
25.4 |
32.7 |
|
33.9 |
|
|
EBITDA margin, % |
? |
|
12.2% |
17.8% |
22.0% |
27.2% |
23.3% |
|
28.4% |
|
Net margin, % |
? |
|
7.90% |
10.4% |
13.2% |
14.5% |
16.7% |
|
21.6% |
|
FCF yield, % |
? |
|
2.89% |
2.82% |
2.81% |
4.07% |
5.31% |
|
5.53% |
|
ROE, % |
? |
|
6.52% |
9.05% |
11.2% |
13.2% |
14.7% |
|
19.6% |
|
ROA, % |
? |
|
4.32% |
6.52% |
7.68% |
9.18% |
10.3% |
|
13.6% |
|
|
P/E |
? |
|
89.9 |
74.1 |
51.6 |
40.2 |
29.5 |
|
22.5 |
|
P/FCF |
|
|
34.6 |
35.4 |
35.6 |
24.6 |
18.8 |
|
18.1 |
|
P/S |
? |
|
7.11 |
7.69 |
6.82 |
5.82 |
4.93 |
|
4.85 |
|
P/BV |
? |
|
5.86 |
6.85 |
5.86 |
5.38 |
4.34 |
|
4.41 |
|
EV/EBITDA |
? |
|
56.4 |
40.5 |
29.5 |
20.5 |
19.6 |
|
16.0 |
|
Debt/EBITDA |
|
|
-1.96 |
-2.75 |
-1.45 |
-0.97 |
-1.60 |
|
-1.03 |
|
|
R&D/CAPEX, % |
|
|
1 402% |
2 811% |
1 996% |
1 914% |
2 987% |
|
2 819% |
|
|
CAPEX/Revenue, % |
|
|
2.06% |
1.11% |
1.50% |
1.62% |
1.19% |
|
1.20% |
|
| Neurocrine Biosciences shareholders |
